The Survival Rate Comparison of Non Small Cell Lung Carcinoma Patients Who Are Given by Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor and Those Given by First-Line Chemotherapy Treatment. NMSJ 2022, 6 (2), 103-115. https://doi.org/10.20956/nmsj.v6i2.18857.